From: Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review
Author (year) | Disease | N | Discriminative | Controls | N | No. of markers | Sensitivity/Specificity (%)* | Ref. |
---|---|---|---|---|---|---|---|---|
Caldeira (2011) | Asthma | 35 | + | Controls | 15 | 28 | CVV: 88% | [17] |
Caldeira (2012) | Asthma | 32 | + | Controls | 27 | 9 | 98/93 | [18] |
Dallinga (2010) | Asthma | 63 | + | Controls | 57 | 8 to 22 | 89 - 100/95 - 100 | [19] |
Dragonieri (2007) | Mild asthma | 10 | + | Controls | 10 | N.S. | CVV: 100% (M-distance 5.32) | [10] |
Severe asthma | 10 | + | Controls | 10 | N.S. | CVV: 90% (M-distance 2.77) | ||
Fens (2009) | Asthma | 20 | + | Non-smoking controls | 20 | N.S. | CVV: 95% (p < 0.001) | [15] |
Asthma | 20 | + | Smoking controls | 20 | N.S. | CVV: 93% (p < 0.001) | ||
Ibrahim (2011) | Asthma | 35 | + | Non-smoking controls | 23 | 15 | CVV: 83% (PPV: 0.85, NPV: 0.89) | [20] |
Montuschi (2010) | Asthma | 27 | + | Controls | 24 | N.S. | DP: 88% | [22] |
Timms (2012) | Asthma | 20 | + | Controls | 7 | N.S. | CVV: 70% (p = 0.047) | [32] |
COPD | 17 | + | Controls | 7 | N.S. | M-distance: 3.601 (p < 0.01) | ||
Cristescu (2011) | Emphysema | 43 | - | (Former) smoking controls | 161 | 1 | AUC: 0.56 (CI: 0.45-0.66) | [26] |
Basanta (2010) | COPD | 20 | + | Smoking controls | 6 | N.S. | 88/81 | [25] |
Fens (2009) | COPD | 30 | +/− | Smoking controls | 20 | N.S. | CVV: 66% (p < 0.01) | [15] |
COPD | 30 | - | Non-smoking controls | 20 | N.S. | CVV: N.S. | ||
Hattesohl (2011) | COPD | 23 | +/− | Controls | 10 | N.S. | CVV: 68% (p < 0.001) | [28] |
Hauschild (2012) | COPD | 84 | + | Controls | 35 | 120 | 87 - 98/71 - 86 | [29] |
Phillips (2012) | COPD | 119 | + | Controls | 63 | N.S. | 79/64 | [31] |
Van Berkel (2010) | COPD | 50 | + | Controls | 29 | 6 to 13 | 98 - 100/88 - 100 | [33] |
COPD (validation) | 16 | + | Controls (validation) | 16 | 6 | 100/81 | ||
Robroeks (2010) | CF | 48 | + | Controls | 57 | 22 | 100/100 | [14] |
Bajtarevic (2009) | LC | 65 | + | Controls | 31 | 15 to 21 | 71 - 80/100 - 100 | [41] |
D’Amico (2010) | LC | 28 | + | Controls | 36 | N.S. | 85/100 | [44] |
Di Natale (2003) | LC | 35 | + | Controls | 18 | N.S. | 100/94 | [11] |
Dragonieri (2009) | NSCLC | 10 | + | Controls | 10 | N.S. | CVV: 90% (M-distance 2.96) | [12] |
Gaspar (2009) | LC | 18 | + | Controls | 10 | 10 | 100/100 | [46] |
Gordon (1985) | LC | 12 | + | Controls | 9 | 22 | DP > 80% | [47] |
Ligor (2009) | LC | 65 | +/− | Controls | 31 | 8 | 51/100 | [49] |
Machado (2005) | LC | 14 | + | Controls | 20 | N.S. | CVV: 72% (M-distance: 3.25) | [13] |
Mazzone (2007) | NSCLC | 49 | - | Controls | 21 | N.S. | 57/78 | [50] |
Peng (2009) | LC | 40 | + | Controls | 56 | 42 | 2 PCA clusters: 100% discrimination | [52] |
Peng (2010) | PLC | 30 | + | Controls | 22 | 33 | 2 PCA clusters: 100% discrimination | [53] |
Phillips (2003) | PLC | 67 | + | Controls | 41 | 9 | 85/81 | [7] |
Phillips (2007–2008) | PLC | 193 | + | Controls | 211 | 16 to 30 | 85 - 85/80 - 81 | |
Poli (2010) | NSCLC | 40 | + | Controls | 38 | 7 | 90/92 | [59] |
Steeghs (2007) | LC | 11 | + | Controls | 57 | 2 | AUC: 0.81 | [64] |
Westhoff (2009) | LC | 32 | + | Controls | 54 | 23 | 100/100 | [67] |
Chapman (2012) | MPM | 10 | + | Controls | 32 | N.S. | 90/91 | [68] |
Dragonieri (2012) | MPM | 13 | + | Controls | 13 | N.S. | CVV: 85% (p < 0.001) | [69] |
Phillips (2007) | Patients suspected of TB | 42 | + | Controls | 59 | N.S. (≈7) | 100/100 | [77] |
Phillips (2012) | Patients with TB | 130 | +/− | Controls | 121 | 8 | 71/72 | [79] |